Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease

Hyeok Hee Lee, Han Ah Lee, Eun Jin Kim, Hwi Young Kim, Hyeon Chang Kim, Sang Hoon Ahn, Hokyou Lee, Seung Up Kim

Research output: Contribution to journalArticlepeer-review

11 Scopus citations


Objective We explored clinical implications of the new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) by assessing its prevalence and associated cardiovascular disease (CVD) risk. Design From nationwide health screening data, we identified 9 775 066 adults aged 20-79 who underwent health examination in 2009. Participants were categorised into four mutually exclusive groups: (1) MASLD; (2) MASLD with increased alcohol intake (MetALD); (3) MASLD with other combined aetiology (the three collectively referred to as MASLD/related steatotic liver disease (SLD)); and (4) no MASLD/related SLD. SLD was determined by fatty liver index ≥30. The primary outcome was CVD event, defined as a composite of myocardial infarction, ischaemic stroke, heart failure or cardiovascular death. Results The prevalence of MASLD, MetALD and MASLD with other combined aetiology was 27.5%, 4.4% and 1.5%, respectively. A total of 8 808 494 participants without prior CVD were followed up for a median of 12.3 years, during which 272 863 CVD events occurred. The cumulative incidence and multivariable-adjusted risk of CVD were higher in participants with MASLD/related SLD than in those without (HR 1.38 (95% CI 1.37 to 1.39)). Multivariable-adjusted HR (95% CI) of CVD events was 1.39 (1.38 to 1.40) for MASLD, 1.28 (1.26 to 1.30) for MetALD and 1.30 (1.26 to 1.34) for MASLD with other combined aetiology compared to the absence of any of these conditions. CVD risk was also higher in participants with metabolic dysfunction-associated fatty liver disease or non-alcoholic fatty liver disease than in those without the respective condition. Conclusion Over one-third of Korean adults have MASLD/related SLD and bear a high CVD risk.

Original languageEnglish
Pages (from-to)533-540
Number of pages8
Issue number3
StatePublished - 31 Oct 2023

Bibliographical note

Publisher Copyright:
© Author(s) (or their employer(s)) 2024. No commercial re-use. See rights and permissions. Published by BMJ.


Dive into the research topics of 'Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease'. Together they form a unique fingerprint.

Cite this